Abstract #3737: A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models
Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Cristina Ponti(University of Milan), Dario Ballinari(Nerviano Medical Sciences), Francesco Colotta(Humanitas University), Paola Magnaghi(Nerviano Medical Sciences), Paolo Orsini(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Valter Croci(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Gemma Texidó(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Ettore Perrone(Nerviano Medical Sciences), Jaqueline Lansen(Nerviano Medical Sciences), Enrico Pesenti, Andrea Borgia(Nerviano Medical Sciences), Fabio Stellari(Chiesi Foundation), Tiziano Bandiera(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences)
Cancer Research
May 1, 2009
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury
|Proceedings of the National Academy of Sciences|2004|339
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
NK Cells and Cancer
|The Journal of Immunology|2007|296
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205